Viridian Therapeutics wins FDA approval for Lumvoa for thyroid eye disease, its first commercial product
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $302.00K | $314.00K | $1.77M | $2.96M | $1.05M | $4.46M | $8.39M | $4.00M |
| Cost of Revenue | N/A | N/A | N/A | N/A | $28.30M | N/A | $30.42M | $19.62M |
| Gross Profit | $302.00K | $314.00K | $1.77M | $2.96M | $-27.25M | $4.46M | $-22.04M | $-15.62M |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | -2595.62% | 100.00% | -262.76% | -390.21% |
| Operating Expenses | $299.34M | $254.76M | $136.08M | $82.69M | $83.13M | $46.44M | $11.05M | $10.91M |
| Operating Income | $-299.04M | $-254.45M | $-134.30M | $-79.73M | $-110.38M | $-41.98M | $-33.08M | $-26.53M |
| Operating Margin | -99018.21% | -81035.03% | -7579.23% | -2690.79% | -10512.38% | -941.02% | -394.51% | -662.80% |
| Net Income | $-269.95M | $-237.73M | $-129.87M | $-79.41M | $-110.72M | $-41.87M | $-32.70M | $-26.51M |
| Net Margin | -89387.09% | -75711.46% | -7329.23% | -2680.16% | -10544.29% | -938.65% | -389.97% | -662.30% |
| EPS (Basic) | $-3.98 | $-5.31 | $-3.91 | $-6.66 | $-31.20 | $-20.31 | $-16.57 | $-20.66 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |